Verus Pharmaceuticals

From Wikipedia the free encyclopedia

Verus Pharmaceuticals
TypePrivately held company
IndustryPharmaceuticals
FoundedNovember 2002
HeadquartersSan Diego, California, United States
Key people
Cam L. Garner, chairman & CEO
Robert W. Keith, President & COO
ProductsTwinject
Websitewww.veruspharm.com

Verus Pharmaceuticals was a privately held pharmaceutical company based in San Diego, California, USA. It was founded in November 2002 by three former Dura Pharmaceuticals executives, Bob Keith, Peter Schineller and Cam Garner, with an initial focus on the treatment of asthma, allergies and related diseases and conditions, specifically in children.

Verus is best known for its development and manufacturing of Twinject, the first (and currently only) two-dose epinephrine autoinjector. The Twinject was later licensed to Paladin Labs for manufacturing and distribution in Canada (released in September 2006.) The licence for manufacturing and distribution in Europe (and option for worldwide distribution) was sold to UCB.

Verus Pharmaceuticals was dissolved in March 2008 after selling its Twinject product to Sciele Pharma for $29 million.

In 2009, Verus filed a lawsuit against AstraZeneca and Tika Lakemedel, "seeking $1.3 billion on claims of fraud, breach of contract, and conversion."[1]

See also[edit]

References[edit]


  1. ^ "Verus Pharmaceuticals Announces a Lawsuit Against AstraZeneca AB and Tika Lakemedel AB". BioSpace. Retrieved May 27, 2020.